SciELO - Scientific Electronic Library Online

 
vol.48 número2Infección por Helicobacter pylori en pacientes con mucosa sana y con gastritis erosivaEvaluación del uso del esquema de paclitaxel con carboplatino en pacientes con cáncer de mama metastásico índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Medicina

versión impresa ISSN 0034-7523versión On-line ISSN 1561-302X

Resumen

SORIANO GARCIA, Jorge L et al. Cyclophosphamide and Methrotexate as a Metronome-chemotherapy used in patients with progressing metastatic breast cancer. Rev cubana med [online]. 2009, vol.48, n.2. ISSN 0034-7523.

Introduction: Continuous use of low doses of cytotoxic agents during lengthy periods has shown to be an alternative to treat metastatic breast cancer (MBC), an opening in face of a resistance of known and beneficial drugs in quality of life. Methods: From April, 2002 and December, 2005, a total of 28 patients was assessed with a progressing MBC, Eastern Cooperative Oncology Group (ECOG)= 2, previously treated with, or at least, a chemotherapy line for metastatic disease, and the respective informed consent from patients. We administered: 2.5 mg/b.i.d. of oral Methrotexate during two days, and 50 mg/quotid of Cyclophosphamide during 5 days weekly. We analyzed survival rate by Kaplan-Meier method. Results: We found a mean age of 56 years (36-74), and 13 patients with more than a metastatic site. There was an objective response (RC + RP) in 14 patients, EE en 8, and progression in 6. Average time to obtain a response was of 2.8 months (CI 1.9-3.5), and average length response (in respondents), 7.9 months (IC 3.7-16.2). The metastatic sites with a higher response rate were: skin/soft parts, and liver, and the more observed ones were: anemia and 2-degree leukopenia in 11 patients, 3 degree hepatic toxicity in one patient, and 5 degree in 5 of them; 3 degree nausea in 3 patients, and 2 degree en 6 of them. Conclusions: Metronome-chemotherapy is a very useful therapeutical option in MBC by its benefits, advantages of oral pathway, a scarce toxicity and a low cost.

Palabras clave : Metastatic breast cancer; metronome-chemotherapy..

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons